The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The present invention involves new and original sigma receptors Ligands: (Mono-or dialkylaminoalkyl)-[gamma]-butyro-lactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl [alpha]-[(adamantyl-1)ben-zyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or di-astereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues wi...

The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin sanguinarine amiodarone chlorpromazine clomiphene dihydroergotamine dipyridamole emetine ephedrine prochlorperazine promazine propiomazine aminacrine fluphenazine fenoterol peruvoside proglumide atenolol nerifolin nefopam cycloheximide avermectin B1 bepridil cinnarizine ethisterone pararosaniline methylbenzethonium niclosamide p...

The present invention provides a radiolabeled astemizole of formula (III)and a process for preparing the radiolabeled astemizole of formula III.

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition effective for prophylaxis and/or treatment of allergic diseases such as atopic dermatitis bronchial asthma and allergic rhinitis. SOLUTION: The prophylactic and/or therapeutic agent for allergic diseases comprises a histamine H1 receptor antagonist and a CCR3 (C-C chemokine receptor 3) antagonist. IgE production inhibitor comprises the histamine H1 receptor antagonist and the CCR3. The histamine H1 receptor antagonist is selected fro...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...